# Eventide

> Eventide is a VC fund in Omaha backing Biotechnology and Health Care. See 60 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Omaha, United States
- Total investments: 60
- Last investment: Jul 2026
- Lead investor: 25%
- Last fund: Mar 2010
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/rob-cheriakalath-john-b7735712
- Website: http://www.eventidefunds.com

Eventide is a VC fund in Omaha focused on Biotechnology and Health Care. Evantide Asset Management, LLC provides investments for individuals, financial advisors, and institutions.

## Contacts

5 contacts available for Eventide. Shizune tracks 3 team members at Eventide. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/eventide-asset-management?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 39 | 65% |
| Health Care | 27 | 45% |
| Therapeutics | 17 | 28% |
| Medical | 14 | 23% |
| Pharmaceutical | 14 | 23% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 15 | 25% |
| Post-IPO Equity | 13 | 22% |
| Series C | 12 | 20% |
| Series D | 4 | 7% |
| Private Equity | 4 | 7% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 40 | 67% |
| United Kingdom | 2 | 3% |
| China | 1 | 2% |
| Canada | 1 | 2% |
| France | 1 | 2% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dolores Bamford | Co-Chief Investment Officer | 0 | https://shizune.co/investors/profile/dolores-bamford-3f2e |
| Finny Kuruvilla | Chief Investment Officer, Portfolio Manager | 3 | https://shizune.co/investors/profile/finny-kuruvilla |
| Robin Cheriakalath John | Co-founder and Chief Executive Officer | 0 | https://shizune.co/investors/profile/robin-cheriakalath-john |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Leo Cancer Care | Leo Cancer Care develops radiation therapy technologies that support cancer treatment in an upright patient position. The company designs integrated imaging, patient positioning, and treatment systems that are compatible with fixed radiation beam platforms used in photon and particle therapy. Its technology focuses on supporting the radiotherapyworkflow from patient simulation through treatment while enabling multiple radiation therapy modalities. Leo Cancer Care also collaborates with healthcare providers, research institutions, and industry partners to evaluate and advance the clinical use of upright radiotherapy systems. In addition to developing treatment technologies, the company works on expanding access to radiotherapy through solutions that aim to improve workflow efficiency and compatibility with existing treatment infrastructure. | $65M | Series D | Jul 08, 2026 |  |
| Flare Therapeutics | Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M | Series C | Jun 30, 2026 |  |
| Quince Therapeutics | Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M | Post-IPO Equity | May 18, 2026 |  |
| Adlai Nortye | Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $150M | Post-IPO Equity | Apr 16, 2026 |  |
| Ovid Therapeutics | Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based onkey insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe. | $60M | Post-IPO Equity | Mar 17, 2026 |  |
| Relmada Therapeutics | Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor(NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.() | $160M | Post-IPO Equity | Mar 09, 2026 |  |
| Sutro Biopharma | Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. | $110M | Post-IPO Equity | Feb 10, 2026 |  |
| Ovid Therapeutics | Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based onkey insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe. | $81M | Post-IPO Equity | Oct 03, 2025 |  |
| Belite Bio | Belite Bio focused on first-in-class therapeutics targeting untreatable inherited orphan diseases and age-related metabolic diseases, including atrophic age-related macular degeneration, stargardt disease, and nonalcoholic steatohepatitis. They develop anti-RBP4 therapies to treat age-related metabolic diseases, including macular degeneration,liver disease, and diabetes. Their technology platform effectively reduces circulating levels of RBP4, a vitamin A transporter protein linked to the development of aging metabolic diseases, including dry age-related macular degeneration, liver disease, and diabetes. | $125M | Post-IPO Equity | Sep 08, 2025 |  |
| BBOT | BridgeBio Oncology Therapeutics operates as a biopharmaceutical company. | $261M | Post-IPO Equity | Aug 11, 2025 |  |

10 of 60 investments shown.

## Co-investors
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 16 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 14 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 11 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 10 deals together
- [Soleus Capital](https://shizune.co/investors/profile/soleus-capital) — VC Fund, 10 deals together
- [Cowen Healthcare Investments](https://shizune.co/investors/profile/cowen-healthcare-investments) — VC Fund, 9 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Eventide invest in?

Eventide invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Post-IPO Equity stage. Most of the 60 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Eventide?

Public channels for Eventide include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Eventide?

The team at Eventide includes Dolores Bamford (Co-Chief Investment Officer), Finny Kuruvilla (Chief Investment Officer, Portfolio Manager) and Robin Cheriakalath John (Co-founder and Chief Executive Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co